Calidi Biotherapeutics, Inc.
CLDI · XNYSCIK 1855485fmd_1FRCRY9K693335S1YF0DN1YCNZManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 21 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total revenues | 0 | – | – | – |
| Research and development | 7 | 13 | 9 | 10 |
| Selling, general and administrative | 16 | 16 | 13 | 11 |
| Total operating expenses | 23 | 29 | 22 | 20 |
| Operating income | (23) | (29) | (22) | (20) |
| Interest expense | 0 | 1 | 1 | 0 |
| Other non-operating income (expense) | (2) | (0) | (0) | 0 |
| Income before taxes | (25) | (29) | (22) | (20) |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (25) | (29) | (22) | (20) |
| Net income | (25) | (29) | (22) | (20) |
| Net income to common shareholders | 1 | (29) | (24) | (26) |